RxDoctor Payments Data

Nighat Sarwar, MD

Neurology · Fresno, CANPI 1003809989

Payments from drug & device makers

$126,632in general payments, 2019–2025

Across 1,835 payments — averaging $69.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$78K
  • EMD Serono, Inc.$10K
  • AstraZeneca$5K
  • Sanofi$4K
  • AbbVie$3K
  • Novartis$3K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$26,05421%
  • Speaking & faculty fees$57,98046%
  • Travel & lodging$5,8745%
  • Food & beverage$36,46729%
  • Education$2570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen220$77,857
EMD Serono, Inc.50$10,041
AstraZeneca(2 entities)92$4,829
Sanofi44$3,940
AbbVie(2 entities)155$2,916
Novartis157$2,677
Genentech USA, Inc.73$1,585
Acadia Pharmaceuticals Inc70$1,432
Teva Pharmaceuticals USA, Inc.77$1,424
UCB, Inc.69$1,345
Boston Scientific8$1,313
Genentech, Inc.3$1,116
Amgen(2 entities)33$910
Argenx US, Inc.33$875
Eisai Inc.44$873
Sunovion Pharmaceuticals Inc.78$773
Bristol Myers Squibb45$749
Neurocrine Biosciences, Inc.28$710
SK Life Science, Inc.40$672
Lilly USA, LLC37$623
Kyowa Kirin, Inc.26$602
Pfizer48$597
Harmony Biosciences LLC16$567
Amneal Pharmaceuticals LLC32$541
Jazz Pharmaceuticals Inc.15$506
Lundbeck LLC25$502
Johnson & Johnson(2 entities)19$456
MDD US Operations, LLC13$373
Otsuka America Pharmaceutical, Inc.19$362
Sumitomo Pharma America, Inc.18$290
Almatica Pharma LLC13$273
GE HealthCare11$272
Merz Pharmaceuticals, LLC10$271
Mallinckrodt Hospital Products Inc.13$245
Axsome Therapeutics, Inc.9$237
Impel Pharmaceuticals Inc.13$224
Banner Life Sciences, LLC11$223
TG Therapeutics, Inc.9$222
Avadel CNS Pharmaceuticals, LLC11$209
Avanir Pharmaceuticals, Inc.10$192
Octapharma USA, Inc.7$183
Livanova USA, Inc.10$174
Alnylam Pharmaceuticals Inc.7$151
CSL Behring9$147
Neurelis, Inc.7$145
Takeda Pharmaceuticals U.S.A., Inc.5$126
Tanabe Pharma America, Inc.5$117
Biohaven Pharmaceuticals, Inc.10$114
Acorda Therapeutics, Inc6$109
Life Molecular Imaging Ltd5$106
Catalyst Pharmaceuticals, Inc.5$106
Nevro Corp.2$96
Supernus Pharmaceuticals, Inc.4$95
Grifols USA, LLC4$91
Mallinckrodt Enterprises LLC3$79
Merz North America, Inc.3$76
Biohaven Pharmaceutical Holding Company Ltd.4$75
Abbott3$67
Adamas Pharmaceuticals, Inc.4$61
Sanofi-aventis U.S. LLC3$61

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,632 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$3,232,973
Medicare patients
584
Services billed
140,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab25$296,496
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$290,035
VumerityDiroximel Fumarate26$215,562
OctagamImmun Globg(Igg)/Malt/Iga Ov5011$206,584
NuplazidPimavanserin Tartrate30$192,810
CopaxoneGlatiramer Acetate20$138,474
BetaseronInterferon Beta-1b14$122,066
TysabriNatalizumab12$96,236
Glatiramer Acetate30$73,546
RytaryCarbidopa/Levodopa53$67,075
RexultiBrexpiprazole43$58,834
BotoxOnabotulinumtoxina40$50,904
XcopriCenobamate18$34,982
KeppraLevetiracetam29$32,753
NeuproRotigotine32$32,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tysabri$77,857$311,79838 claims
CSL BehringPrivigen$147$290,03513 claims
PfizerOctagam, Dilantin$597$208,45423 claims
Acadia Pharmaceuticals IncNuplazid$1,432$192,81030 claims
Teva Pharmaceuticals USA, Inc.Copaxone$1,424$138,47420 claims
AbbVieBotox, Namzaric$2,916$71,35863 claims
Amneal Pharmaceuticals LLCRytary$541$67,07553 claims
Otsuka America Pharmaceutical, Inc.Rexulti$362$58,83443 claims
UCB, Inc.Neupro, Vimpat$1,345$54,17452 claims
SK Life Science, Inc.Xcopri$672$34,98218 claims
AstraZenecaBrilinta$4,829$5,52713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →